No differences in survival were observed in patients who harboured both LKB1 and KRAS mutations compared with those with KRAS or LKB1 alone but the total number of patients with both mutations who had stages I or II NSCLC was small (n=9; data not shown). This evidence concerns the gene KRAS and non-small cell lung carcinoma.